Precision BioSciences, Inc. (DTIL), a clinical-stage gene editing company, on Wednesday shared promising initial data from its Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV, a novel gene editing therapy for chronic Hepatitis B.
The PBGENE-HBV therapy, which is delivered via a lipid nanoparticle or LNP encapsulated ARCUS mRNA, was found to be safe and well-tolerated in all three participants at the lowest dose level 0.2 mg/kg after the first administration.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com